Video

Can Biosimilars Reduce Specialty Spending?

David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.

David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.

Related Videos
Pharmacist helping a patient with medication -- Image credit: Clayton D/peopleimages.com | stock.adobe.com
Patient receiving cancer treatment infusion -- Image credit: UlrikaArt | stock.adobe.com